Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (177)	3/4/2002 11:21:43 PM
From: Miljenko Zuanic	Respond to of 631

J Clin Invest, March 2002, Volume 109, Number 5, 671-679 Copyright ©2002 by the American Society for Clinical Investigation -------------------------------------------------------------------------------- Article Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model Thomas M. Zollner1, Maurizio Podda1, Christine Pien2, Peter J. Elliott2, Roland Kaufmann1 and Wolf-Henning Boehncke1 1 Department of Dermatology, J.W. Goethe University of Frankfurt, Frankfurt, Germany 2 Millennium Pharmaceuticals Inc., Cambridge, Massachusetts, USA Address correspondence to: Thomas M. Zollner, Schering AG, Research Business Unit Dermatology, Müllerstrasse 178, D-13342 Berlin, Germany. Phone: 49-30-468-17235; Fax: 49-30-468-97235; E-mail: Thomas.Zollner@Schering.de. Received for publication March 13, 2001, and accepted in revised form January 28, 2002. There is increasing evidence that bacterial superantigens contribute to inflammation and T cell responses in psoriasis. Psoriatic inflammation entails a complex series of inductive and effector processes that require the regulated expression of various proinflammatory genes, many of which require NF-B for maximal trans-activation. PS-519 is a potent and selective proteasome inhibitor based upon the naturally occurring compound lactacystin, which inhibits NF-B activation by blocking the degradation of its inhibitory protein IB. We report that proteasome inhibition by PS-519 reduces superantigen-mediated T cell–activation in vitro and in vivo. Proliferation was inhibited along with the expression of very early (CD69), early (CD25), and late T cell (HLA-DR) activation molecules. Moreover, expression of E-selectin ligands relevant to dermal T cell homing was reduced, as was E-selectin binding in vitro. Finally, PS-519 proved to be therapeutically effective in a SCID-hu xenogeneic psoriasis transplantation model. We conclude that inhibition of the proteasome, e.g., by PS-519, is a promising means to treat T cell–mediated disorders such as psoriasis.